Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After Inotuzumab: New Platforms Promise More Than Better Antibody-Drug Conjugates

Executive Summary

Versatile next-generation antibody-drug conjugate platforms promise to turn out ADCs with better specificity and safety than current technologies, as well as combination therapeutics like bi-specific antibodies, but old-school molecules continue to move through clinical trials and gain approval.


Related Content

Keeping Track: Four Novel Agents Clear FDA; Two Complete Response Letters Issued
Back To Her Biotech Roots: An Interview With Anna Protopapas
Deals Of The Week: Value Surprise!
Pfizer Oncology: Big Strides But Not Blockbuster Size
AstraZeneca/MedImmune Synergies An Advantage In Immune-Mediated Cancer Therapies
Ambrx Links Its ADC Technology To Japan’s Astellas In Oncology Deal
Celgene Dips Into The Antibody Well Once More, Partners With Sutro
Merck, Ambrx Partner In Effort To Create Better-Targeted Drug Conjugates
Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris
Mylotarg Pulled Off Market, But Pfizer Continues Search For Appropriate Population


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts